Eli Lilly Kinsale Limited, Dunderrow, Kinsale, Co. Cork P17 NY71, Ireland; School of Chemical and Bioprocess Engineering, University College Dublin, Belfield, Dublin 4 D04 V1W8, Ireland.
Eli Lilly Kinsale Limited, Dunderrow, Kinsale, Co. Cork P17 NY71, Ireland.
J Pharm Biomed Anal. 2024 Jan 20;238:115798. doi: 10.1016/j.jpba.2023.115798. Epub 2023 Oct 13.
Aurintricarboxylic acid (ATA) is an excipient that can be added to the therapeutic protein manufacturing process as a component of the Chinese hamster ovary (CHO) cell culture media. ATA inhibits cell apoptosis and promotes cell growth in both serum-free and protein-free media. The addition of ATA is beneficial to the manufacturing process at the cell growth stage, however, residual ATA not consumed by cells can have toxicological effects on patients and its removal is required during downstream processing. To ensure manufacturing control and patient safety, the determination of residual ATA during downstream processing of biotherapeutics is required. The aim of this study was to develop and validate a liquid chromatography triple quadrupole mass spectrometry method for monitoring process clearance of ATA during downstream processing. Chromatographic separation of ATA was achieved using a 50 × 3 mm, 3 µm Imtakt Cadenza HS-C18 column and a triple quadrupole mass spectrometer operated in selected reaction monitoring mode was used for sensitive and specific detection. Linearity was assessed over a range of 62.5 ng/mL to 2000 ng/mL. Accuracy and precision were within 20% of the theoretical spike levels across the three concentration levels evaluated utilising two different antibodies, an IgG1 and an IgG4. Analyte specificity and selectivity were deemed acceptable based on no extraneous peaks detected. The method was successfully applied to monitoring process clearance of ATA in a tangential flow filtration (TFF) unit operation for downstream processing of monoclonal antibodies.
苍尿酸(ATA)是一种赋形剂,可作为无血清和无蛋白培养基中的一种成分添加到治疗性蛋白的制造工艺中。ATA 可抑制细胞凋亡并促进细胞在无血清和无蛋白培养基中的生长。ATA 的添加有利于细胞生长阶段的制造过程,但是,未被细胞消耗的残留 ATA 可能对患者具有毒理学作用,因此在下游处理过程中需要去除。为了确保制造控制和患者安全,需要在生物治疗剂的下游处理过程中确定残留的 ATA。本研究旨在开发和验证一种液相色谱三重四极杆质谱法,用于监测下游处理过程中 ATA 的工艺清除率。采用 50×3mm、3μm Imtakt Cadenza HS-C18 柱实现 ATA 的色谱分离,三重四极杆质谱仪以选择反应监测模式操作,用于灵敏和特异性检测。线性评估范围为 62.5ng/mL 至 2000ng/mL。使用两种不同的抗体(IgG1 和 IgG4)评估了三个浓度水平,结果表明准确度和精密度均在理论加标水平的 20%以内。根据未检测到额外峰,认为分析物的特异性和选择性可接受。该方法成功应用于监测单克隆抗体下游处理的切向流过滤(TFF)单元操作中 ATA 的工艺清除率。